Haleon (HLN) Q3 2024 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 TU earnings summary
3 Feb, 2026Executive summary
Q3 organic revenue grew 6.1%, balanced between price (3.3%) and volume/mix (2.8%), with all regions and categories contributing and Power Brands up 5.4%.
Adjusted operating profit grew 7.4% in Q3, with YTD organic profit up 9.7% and margin expansion; reported operating profit rose 20.7% to £705m, including a £121m gain from the NRT divestment.
All three regions—North America, EMEA & LATAM, and Asia Pacific—contributed to growth, with China and India delivering double-digit gains.
Over £1bn returned to shareholders YTD via buybacks and dividends; £500m share buyback completed.
Increased stake in China JV to 88% for ~£0.5bn, with a pathway to full ownership, and completed divestments of NRT business outside the US and ChapStick.
Financial highlights
Q3 revenue: £2,780m (down 0.6% reported, up 6.1% organic); 9M revenue: £8,474m (down 0.7% reported, up 4.4% organic).
Q3 adjusted operating profit: £639m (23.0% margin, up 30bps organically, down 160bps reported); 9M adjusted operating profit: £1,932m (22.8% margin, up 120bps organically).
Power Brands grew 5.4% in Q3.
FX and M&A headwinds reduced reported revenue and profit; net M&A had a £30m negative impact in Q3.
Q3 basic EPS: 13.2p (up from 11.4p in Q3 2023).
Outlook and guidance
FY 2024 organic revenue growth expected at 4-6% and high single-digit organic profit growth; guidance reaffirmed.
FX expected to have a ~4% adverse impact on revenue and 6-6.5% on adjusted operating profit for FY 2024.
Net interest expense for FY 2024 estimated at ~£320m; adjusted effective tax rate 24-25%.
Medium-term guidance: annual organic revenue growth of 4-6%, profit growth ahead of revenue, net debt/EBITDA around 2.5x, and dividend growth at least in line with adjusted earnings.
Confident in continued volume growth and balanced price/volume mix into Q4 and 2025.
Latest events from Haleon
- Gross margin rose 220 bps as profit and shareholder returns grew, despite U.S. and cold/flu softness.HLN
H2 2025 (Q&A)25 Feb 2026 - 3% organic growth, 10.5% profit growth, and strong shareholder returns in 2025.HLN
H2 202525 Feb 2026 - Oral health and emerging markets offset U.S. softness as savings and innovation drive growth.HLN
Barclays 18th Annual Global Consumer Staples Conference 20253 Feb 2026 - Strong H1 organic growth, margin expansion, and cash flow support upgraded FY outlook.HLN
H1 2024 (Q&A)2 Feb 2026 - Power brands and agile strategies drive EMEA & LATAM growth, led by pharmacy and innovation.HLN
21st Annual dbAccess Global Consumer Conference 20241 Feb 2026 - Strong organic growth, margin expansion, and robust shareholder returns in 2024.HLN
H2 202430 Jan 2026 - Sustained growth, margin gains, and innovation drive strong performance and strategic flexibility.HLN
17th Annual Global Consumer Staples Conference 202422 Jan 2026 - Growth targets of 4-6% are supported by innovation, divestments, and global expansion.HLN
Bernstein's 21st Pan European Annual Strategic Decisions Conference20 Jan 2026 - Purposeful, data-driven marketing and innovation fuel growth, trust, and brand differentiation.HLN
Fireside Chat19 Jan 2026